Understanding how T-cell acute lymphoblastic leukemia avoids the immune system and finding new treatments.
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications
This study is looking at how T-cell acute lymphoblastic leukemia (T-ALL) manages to hide from the immune system, which makes it tough to treat, especially when it comes back, and it hopes to find new ways to help improve treatments for patients like you by understanding how leukemia cells interact with immune cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11229540 on NIH RePORTER |
What this research studies
This research investigates the ways in which T-cell acute lymphoblastic leukemia (T-ALL) can evade the immune system, making it difficult to treat, especially when it relapses. By analyzing the interactions between leukemia cells and immune cells using advanced single cell sequencing technologies, the study aims to identify new therapeutic targets that could enhance the effectiveness of immunotherapy. The goal is to uncover mechanisms that lead to T-cell dysfunction and to develop strategies to overcome this immune evasion, potentially improving treatment outcomes for patients with T-ALL.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with T-cell acute lymphoblastic leukemia, especially those with relapsed or treatment-refractory disease.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with T-ALL may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for T-ALL, particularly for patients whose disease has not responded to current therapies.
How similar studies have performed: Other research has shown promising results in targeting immune evasion in solid tumors, suggesting that similar approaches may be effective in T-ALL, although this specific area is less explored.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Knoechel, Birgit — University of Utah
- Study coordinator: Knoechel, Birgit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.